Febuxostat, a more recent xanthine oxidase inhibitor (approved by the Food and Drug Administration in 2009), may be a reasonable choice for hyperuricemic patients with CKD as it is cost-effective and well tolerated (Gandhi et al., 2015; Tiku et al., 2018). The gene discussed is XDH; the disease is chronic kidney disease.